Long-Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response With Risankizumab in Patients With Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry

This study from the CorEvitas Psoriasis Registry evaluated the long-term effectiveness of risankizumab in treating moderate-to-severe plaque psoriasis. Involving 163 patients, the study found that after 18 months of continuous treatment, 94.6% of patients with a baseline body surface area (BSA) ≥3% achieved the National Psoriasis Foundation (NPF)-defined acceptable response, and 81.9% reached the target goals. Additionally, 83.7% of patients who achieved a 90% improvement in the Psoriasis Area and Severity Index (PASI90) at 6 months maintained their response at 12 months. This indicates that risankizumab is effective in achieving and maintaining treatment targets in a real-world setting.